Market By Types And Geography | Forecast 2019-2027
According to Triton, the global antithrombotic drugs market is expected to display a positive market trend over the forecast period of 2019-2027, exhibiting a CAGR of 6.61%. The market was assessed to be worth $26194.26 million in the year 2018 and is predicted to generate a revenue of approximately $46566.08 million by the year 2027.
An antithrombotic agent is a drug that restricts the development of blood clots, also called thrombi. Antithrombotic drugs can be used therapeutically for the prevention (primary prevention, secondary prevention) and treatment of a dangerous blood clot (acute thrombus). Antiplatelet drugs restrict the aggregation or migration of platelets and the anticoagulants restrict the ability of the blood to clot. Thrombolytic drugs help dissolve the clots after their formation.
To know more about this report, request a free sample copy.
Thrombosis is caused by three main reasons, which include the abnormal flow of blood, hypercoagulability and injury caused to endothelial cells of the blood vessel wall. These causes are the result of genetic conditions, inactivity, blood vessel damage, smoking, obesity and pregnancy. Presently, thrombosis and related illnesses such as stroke, pulmonary embolism and myocardial infarction are healed with the help of off-patent anticoagulant drugs such as warfarin and heparin. The other types of antithrombotic drugs, namely, aspirin are also known as off-patent. Since a very few patented and effective treatments are present in the market, the companies operating in the pharmaceutical sector have potential opportunities to launch innovative products.
The effective drugs can prove beneficial for the companies due to the growing population, which ensures a steady growth in the requirement for these life-saving drugs. The global antithrombotic or anticoagulant drugs market has been assessed to attain the highest advancement over the forecast period, owing to the high availability of drugs and prevalent disorders associated with thrombosis that requires longer drug administration.
In recent years, a number of effective antithrombotic drugs have been made available in the market and also the prescription pattern for these drugs are the factors that are expected to drive the market growth over the coming years. The branded antithrombotic drugs like Plavix, Cardio, Pletal, Effient, Aspirin, Activase, Lovenox, Xarelto and Pradaxa are also largely contributing to the market growth of antithrombotic drugs globally.
Within this report from Triton on the antithrombotic drugs market, the key insights regarding the industry have been discussed. Also, the market outlook, patent outlook, key drugs in the antithrombotic market, Porter’s five force analysis and key buying outlook have been studied.
The increasing adoption rates of NOACs, government initiatives and increase in Hip and knee replacement surgeries are the major driving factors of the market. On the other hand, the restraining factors like the rising aging population and the higher cost of NOACs are adversely affecting the growth of the market.
To get detailed insights on segments, Download Sample Report.
The key opportunities like the booming healthcare industries and the increasing pervasiveness of coagulation maladies are expected to develop the market in the near future. Besides, the dearth of NOACs remedies in the market and the expiration of patents are the key challenges faced by the market.
The key geographies covered in the antithrombotic drugs market are:
• North America: United States and Canada
• Europe: United Kingdom, Germany, France, Italy, Spain, Russia and Rest of Europe
• Asia-Pacific: China, Japan, India, South Korea, ASEAN countries, Australia & New Zealand and Rest of Asia Pacific
• Latin America: Brazil, Mexico and Rest of Latin America
• The Middle East and Africa: United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of Middle East and Africa
The antithrombotic drugs market is segmented into:
• By types:
O Anti-coagulants:
• By drugs:
O Low molecular weight heparin
O Oral anticoagulants (Vitamin K antagonists)
• By rapid onset anti-coagulant (ROA):
O Oral
O Injectable
• By drug class:
O Factor XA
O DTIS
O Heparin
O Vitamin K Antagonists
• By applications:
O PE
O DVT
O AF
O Other anticoagulants applications
• Anti-platelets:
O Oral anti-platelets
O IV platelets
• Thrombin inhibitors:
O Direct factor XA inhibitors
O Direct thrombin inhibitors
O Thrombolytic agents
The major companies leading the antithrombotic drugs market are Armetheon, Inc., GlaxoSmithKline, Baxter International, Novartis, Abbott Laboratories, Bristol-Myers Squibb Co., Bayer, Johnson & Johnson, CSL Behring, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Ltd., Eli Lilly and Company, Pfizer, Sanofi, Daiichi Sankyo Co., Ltd. and Merck & Co.
The strategic analysis for each of these companies in the antithrombotic drugs market is detailed to study the company share, information about the key market players in this industry and their hold on the market.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ANTITHROMBOTIC
DRUGS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. MARKET
DEFINITION
2.2. PORTER’S
FIVE FORCES OUTLOOK
2.2.1. THREAT
OF NEW ENTRANTS
2.2.2. THREAT
OF SUBSTITUTES
2.2.3. BARGAINING
POWER OF BUYERS
2.2.4. BARGAINING
POWER OF SUPPLIERS
2.2.5. THREAT
OF RIVALRY
2.3. KEY
INSIGHTS
2.4. MARKET
OUTLOOK
2.5. PATENT
OUTLOOK
2.6. KEY
DRUGS IN THE ANTITHROMBOTIC DRUGS MARKET
2.7. KEY
BUYING OUTLOOK
2.8. MARKET
DRIVERS
2.8.1. INCREASING
ADOPTION RATES OF NOACS
2.8.2. GOVERNMENT
INITIATIVES
2.8.3. INCREASE
IN HIP AND KNEE REPLACEMENT SURGERIES
2.9. MARKET
RESTRAINTS
2.9.1. RISING
AGING POPULATION
2.9.2. HIGHER
COST OF NOACS
2.10.
MARKET OPPORTUNITIES
2.10.1.
INCREASING HEALTHCARE
INDUSTRIES
2.10.2.
INCREASING PERVASIVENESS OF
COAGULATION MALADIES
2.11.
MARKET CHALLENGES
2.11.1.
DEARTH OF NOACS REMEDIES IN
THE MARKET
2.11.2.
EXPIRATION OF PATENTS
3. ANTITHROMBOTIC
DRUGS MARKET OUTLOOK - BY TYPES
3.1. ANTICOAGULANTS
3.1.1. ANTICOAGULANTS
BY DRUGS TYPE
3.1.1.1. LOW
MOLECULAR WEIGHT HEPARIN
3.1.1.2. ORAL
ANTICOAGULANTS (VITAMIN K ANTAGONISTS)
3.1.2. ANTICOAGULANTS
BY RAPID ONSET ANTICOAGULANT (ROA)
3.1.2.1. ORAL
3.1.2.2. INJECTABLES
3.1.3. ANTICOAGULANTS
BY DRUG CLASS
3.1.3.1. FACTOR
XA
3.1.3.2. DTIS
3.1.3.3. HEPARIN
3.1.3.4. VITAMIN
K ANTAGONISTS
3.1.4. ANTICOAGULANTS
BY APPLICATIONS
3.1.4.1. PE
3.1.4.2. DVT
3.1.4.3. AF
3.1.4.4. OTHER
ANTICOAGULANTS APPLICATIONS
3.2. ANTIPLATELETS
3.2.1. ORAL
ANTIPLATELETS
3.2.2. IV
ANTIPLATELETS
3.3. THROMBIN
INHIBITORS
3.3.1. DIRECT
FACTOR XA INHIBITORS
3.3.2. DIRECT
THROMBIN INHIBITORS
3.3.3. THROMBOLYTIC
AGENTS
4. ANTITHROMBOTIC
DRUGS MARKET - REGIONAL OUTLOOK
4.1. NORTH
AMERICA
4.1.1. COUNTRY
ANALYSIS
4.1.1.1. THE
UNITED STATES
4.1.1.2. CANADA
4.2. EUROPE
4.2.1. COUNTRY
ANALYSIS
4.2.1.1. THE
UNITED KINGDOM
4.2.1.2. FRANCE
4.2.1.3. GERMANY
4.2.1.4. SPAIN
4.2.1.5. ITALY
4.2.1.6. RUSSIA
4.2.1.7. REST
OF EUROPE
4.3. ASIA-PACIFIC
4.3.1. COUNTRY
ANALYSIS
4.3.1.1. INDIA
4.3.1.2. CHINA
4.3.1.3. JAPAN
4.3.1.4. SOUTH
KOREA
4.3.1.5. ASEAN
COUNTRIES
4.3.1.6. AUSTRALIA
& NEW ZEALAND
4.3.1.7. REST
OF APAC
4.4. MIDDLE
EAST AND AFRICA (MEA)
4.4.1. COUNTRY
ANALYSIS
4.4.1.1. SAUDI
ARABIA
4.4.1.2. TURKEY
4.4.1.3. UNITED
ARAB EMIRATES
4.4.1.4. SOUTH
AFRICA
4.4.1.5. REST
OF MIDDLE EAST AND AFRICA
4.5. LATIN
AMERICA
4.5.1. COUNTRY
ANALYSIS
4.5.1.1. BRAZIL
4.5.1.2. MEXICO
4.5.1.3. REST
OF LATIN AMERICA
5. COMPETITIVE
LANDSCAPE
5.1. ABBOTT
LABORATORIES
5.2. ARMETHEON,
INC.
5.3. BAXTER
INTERNATIONAL
5.4. BAYER
5.5. BOEHRINGER INGELHEIM GMBH
5.6. BRISTOL-MYERS
SQUIBB, CO.
5.7. CSL
BEHRING
5.8. DAIICHI
SANKYO CO., LTD.
5.9. ELI
LILLY AND COMPANY
5.10.
F. HOFFMANN-LA ROCHE, LTD.
5.11.
GLAXOSMITHKLINE
5.12.
JOHNSON & JOHNSON
5.13.
MERCK & CO.
5.14.
NOVARTIS
5.15.
PFIZER
5.16.
SANOFI
6. RESEARCH
& METHODOLOGY
6.1. RESEARCH
SCOPE
6.2. SOURCES
OF DATA
6.3. RESEARCH
METHODOLOGY
TABLE 1 GLOBAL ANTITHROMBOTIC DRUGS MARKET, BY
REGION, 2019-2027 ($ MILLION)
TABLE 2 NUMBERS OF PATENTS ON ANTITHROMBOTICS
AND ANTICOAGULANTS, BY VARIOUS COMPANIES, 2011-2016
TABLE 3 NUMBERS OF PATENTS ON ANTICOAGULANTS, BY
VARIOUS COMPANIES, 2011-2016
TABLE 4 INDIAN GOVERNMENT INITIATIVES IN THE
HEALTHCARE SECTOR
TABLE 5 GLOBAL ANTITHROMBOTIC DRUGS MARKET, BY
TYPES, 2019-2027 ($ MILLION)
TABLE 6 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN
ANTICOAGULANTS, BY DRUGS TYPE, 2019-2027 ($ MILLION)
TABLE 7 LOVENOX DRUG BRAND
TABLE 8 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS,
BY ROA, 2019-2027 ($ MILLION)
TABLE 9 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN
ANTICOAGULANTS, BY DRUG CLASS, 2019-2027 ($ MILLION)
TABLE 10 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN
ANTICOAGULANTS, BY APPLICATIONS, 2019-2027 ($ MILLION)
TABLE 11 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN
ANTIPLATELETS, BY TYPES, 2019-2027 ($ MILLION)
TABLE 12 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN
THROMBIN INHIBITORS, BY TYPES, 2019-2027 ($ MILLION)
TABLE 13 NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET,
BY COUNTRIES, 2019-2027 ($ MILLION)
TABLE 14 EUROPE ANTITHROMBOTIC DRUGS MARKET, BY
COUNTRIES, 2019-2027 ($ MILLION)
TABLE 15 ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET,
BY COUNTRIES, 2019-2027 ($ MILLION)
TABLE 16 MIDDLE EAST AND AFRICA ANTITHROMBOTIC
DRUGS MARKET, BY COUNTRIES, 2019-2027 ($ MILLION)
TABLE 17 LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET,
BY COUNTRIES, 2019-2027 ($ MILLION)
FIGURE
1 GLOBAL ANTITHROMBOTIC DRUGS MARKET
BY REGION 2019-2027 ($ MILLION)
FIGURE
2 RAPIDLY GROWING INDUSTRY IN THE
WORLD (%)
FIGURE
3 GLOBAL ANTITHROMBOTIC DRUGS MARKET
IN ANTICOAGULANTS 2019-2027 ($ MILLION)
FIGURE
4 BLOOD COAGULATION PROCESS
FIGURE
5 GLOBAL ANTICOAGULANTS MARKET IN LOW
MOLECULAR WEIGHT HEPARIN 2019-2027 ($ MILLION)
FIGURE
6 GLOBAL ANTICOAGULANTS MARKET IN LOW
ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) 2019-2027 ($ MILLION)
FIGURE
7 GLOBAL ANTICOAGULANTS MARKET IN
ORAL 2019-2027 ($ MILLION)
FIGURE
8 GLOBAL ANTICOAGULANTS MARKET IN
INJECTABLES 2019-2027 ($ MILLION)
FIGURE
9 GLOBAL ANTICOAGULANTS MARKET IN
FACTOR XA 2019-2027 ($ MILLION)
FIGURE
10 GLOBAL ANTICOAGULANTS MARKET IN DTIS
2019-2027 ($ MILLION)
FIGURE
11 GLOBAL ANTICOAGULANTS MARKET IN
HEPARIN 2019-2027 ($ MILLION)
FIGURE
12 GLOBAL ANTICOAGULANTS MARKET IN
VITAMIN K ANTAGONISTS 2019-2027 ($ MILLION)
FIGURE
13 GLOBAL ANTICOAGULANTS MARKET IN PE
2019-2027 ($ MILLION)
FIGURE
14 GLOBAL ANTICOAGULANTS MARKET IN DVT
2019-2027 ($ MILLION)
FIGURE
15 GLOBAL ANTICOAGULANTS MARKET IN AF
2019-2027 ($ MILLION)
FIGURE
16 GLOBAL ANTICOAGULANTS MARKET IN OTHER
ANTICOAGULANTS APPLICATIONS 2019-2027 ($ MILLION)
FIGURE
17 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN
ANTIPLATELETS 2019-2027 ($ MILLION)
FIGURE
18 GLOBAL ANTIPLATELETS MARKET IN ORAL
ANTIPLATELETS 2019-2027 ($ MILLION)
FIGURE
19 GLOBAL ANTIPLATELETS MARKET IN IV
ANTIPLATELETS 2019-2027 ($ MILLION)
FIGURE
20 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN
THROMBIN INHIBITORS 2019-2027 ($ MILLION)
FIGURE
21 GLOBAL THROMBIN INHIBITORS MARKET IN
DIRECT FACTOR XA INHIBITORS 2019-2027 ($ MILLION)
FIGURE
22 GLOBAL THROMBIN INHIBITORS MARKET IN
DIRECT THROMBIN INHIBITORS 2019-2027 ($ MILLION)
FIGURE
23 GLOBAL THROMBIN INHIBITORS MARKET IN
THROMBOLYTIC AGENTS 2019-2027 ($ MILLION)
FIGURE
24 GLOBAL ANTITHROMBOTIC DRUGS MARKET BY
REGION 2019-2027 ($ MILLION)
FIGURE
25 THE UNITED STATES ANTITHROMBOTIC
DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE
26 CANADA ANTITHROMBOTIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE
27 THE UNITED KINGDOM ANTITHROMBOTIC
DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE
28 FRANCE ANTITHROMBOTIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE
29 GERMANY ANTITHROMBOTIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE
30 SPAIN ANTITHROMBOTIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE
31 ITALY ANTITHROMBOTIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE
32 RUSSIA ANTITHROMBOTIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE
33 REST OF EUROPE ANTITHROMBOTIC DRUGS
MARKET 2019-2027 ($ MILLION)
FIGURE
34 INDIA ANTITHROMBOTIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE
35 CHINA ANTITHROMBOTIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE
36 JAPAN ANTITHROMBOTIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE
37 SOUTH KOREA ANTITHROMBOTIC DRUGS
MARKET 2019-2027 ($ MILLION)
FIGURE
38 ASEAN COUNTRIES ANTITHROMBOTIC DRUGS
MARKET 2019-2027 ($ MILLION)
FIGURE
39 AUSTRALIA AND NEW ZEALAND
ANTITHROMBOTIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE
40 REST OF APAC ANTITHROMBOTIC DRUGS
MARKET 2019-2027 ($ MILLION)
FIGURE
41 SAUDI ARABIA ANTITHROMBOTIC DRUGS
MARKET 2019-2027 ($ MILLION)
FIGURE
42 TURKEY ANTITHROMBOTIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE
43 UNITED ARAB EMIRATES ANTITHROMBOTIC
DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE
44 SOUTH AFRICA ANTITHROMBOTIC DRUGS
MARKET 2019-2027 ($ MILLION)
FIGURE
45 REST OF MIDDLE EAST AND AFRICA
ANTITHROMBOTIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE
46 BRAZIL ANTITHROMBOTIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE
47 MEXICO ANTITHROMBOTIC DRUGS MARKET
2019-2027 ($ MILLION)
FIGURE
48 REST OF LATIN AMERICA ANTITHROMBOTIC
DRUGS MARKET 2019-2027 ($ MILLION)